Skip to main content

Table 3 Glucocorticoid Monotherapy Activity in Phase l and Phase ll (Nonrandomized) Trials

From: Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy

Author [reference], Year Patient Characteristics Treatment Responses
Mass [63], 1964 32 lung cancer (17 epidermoid, 7 adenocarcinoma, 8 undifferentiated) 26 GI, 18 GU, 7 melanoma, 2 breast 25–100 mg flurometholone po per day for 7 weeks followed by taper None
Moertel et al [64], 1964 18 colon, 13 gastric, 9 pancreatic, 5 carcinoid, 12 primary unknown (presumed GI), 6 miscellaneous GI, 1 renal cell 25 mg fluorometholone po every 12 hr for at least 2 months 4 PR (1 colon, 1 gastric, 2 primary unknown)
Johnson et al [65], 1966 44 melanoma, 9 lung carcinoma, 5 ovary, 4 uterus, 4 prostate, 4 kidney, 4 breast, 7 miscellaneous 200–600 mg of NSC-17256 per day po for 8 weeks melanoma (3 CR, 2 PR)
Ramirez et al [66], 1971 24 head and neck, 1 gastric, 36 colorectal, 2 pancreas, 13 lung, 70 breast, 36 cervix, 12 uterus, 9 ovary, 9 prostate, 27 kidney, 2 bladder, 111 melanoma, 1 thyroid, 6 liver, 29 sarcoma, 11 primary unknown, 1 lymphoma, 7 miscellaneous 200–600 mg of NSC-17256 per day po for 6 weeks; average dose 300 mg per day Head and neck (1 PR), breast (1 CR, 8 PR), uterus/cervix (2 PR), ovary (1 PR), prostate (1 CR, 3 PR), melanoma (6 PR), Hodgkin (1 PR)